半枝莲提取物中半枝莲碱A和半枝莲碱B大鼠体内药代动力学研究
Pharmacokinetic Study of Scutebarbatine A and Scutebarbatine B in Rats After Orally Administration of Scutellaria Barbata Extract Using a LC-MS/MS Method
-
摘要: 目的 建立同时测定生物样品中半枝莲碱A和半枝莲碱B的LC-MS/MS分析方法，并对其药代动力学进行研究。方法 血浆样品采用乙酸乙酯萃取，BDS Hypersil C18(50 mm×2.1 mm， 2.4 μm)色谱柱进行梯度洗脱，柱温40 ℃，流动相为乙腈：0.05％甲酸水溶液，流速为0.25 mL/min。电喷雾离子源，MRM模式。大鼠单剂量灌胃500 mg/kg半枝莲提取物后，检测半枝莲碱A和半枝莲碱B的血药浓度，DAS软件对其血药浓度-时间曲线进行拟合，统计矩模型计算药动学参数。结果 半枝莲碱A和半枝莲碱B在0.512~258.0 ng/mL和0.482~241.0 ng/mL间线性关系良好（r2>0.994）；精密度、准确度、提取回收率和基质效应、稳定性均符合生物样品分析要求。半枝莲碱A和半枝莲碱B的AUC(0-t)分别为(88.69±12.4)μg/L·h和(57.09±9.84) μg/L·h，达峰浓度分别为(10.22±1.31)ng/mL和(6.27±0.80)ng/mL。结论 该方法简便、准确、灵敏，可用于半枝莲提取物中半枝莲碱A和半枝莲碱B体内药代动力学研究。Abstract: OBJECTIVE The aim of this study was to develop and validate a LC-MS/MS method to simultaneously determination of Scutebarbatine A and Scutebarbatine B in rat plasma and applicated this method to pharmacokinetic study of Scutebarbatine A and Scutebarbatine B after oral administration of Scutellaria barbata extract. METHODS Plasma samples were prepared with ethyl acetate using liquid-liquid extraction. Then samples were separated by using BDS Hypersil C18(50 mm×2.1 mm， 2.4 μm) with gradient elution program and oven temperature was set at 40 ℃. And the mobile phase was consisted with acetonitrile/water (0.05% formic acid) at a flow rate of 0.25 mL/min. Determination was carried out on a tandem mass spectrometer in positive ion mode using a multiple reaction monitoring (MRM) via a electrospray ionization (ESI) interface. After oral administration of 500 mg/kg Scutellaria barbata extract， plasma samples were collected and analyzed by using a DAS software to analyze to the pharmacokinetic parameters. RESULTS Scutebarbatine A and Scutebarbatine B were liner at the range of 0.512~258.0 ng/mL， 0.482~241.0 ng/mL， respectively with a r2 larger than 0.994. Accuracy， precious， extraction efficiency， matrix effects and stability study were all meet the requirement of the bioanalytical method. The AUC(0-t) for Scutebarbatine A and Scutebarbatine B were (88.69±12.4)μg/L·h， (57.09±9.84)μg/L·h， respectively. And the Cmax for Scutebarbatine A and Scutebarbatine B were (10.22±1.31)ng/mL and (6.27±0.80)ng/mL. CONCLUSION The method was simple， accurate， and sensitive， which could be used for the pharmacokinetic study of Scutebarbatine A and Scutebarbatine B after oral administration of Scutellaria barbata extract.
-
Keywords:
- Scutellaria barbata /
- LC-MS/MS /
- pharmacokinetics
-
-
[1] 郑永红， 韦晓瑜，龙继红. 半枝莲的研究进展[J]. 中草药，2010，41（8）：1406-1408. [2] ZHENG YH， WEI XY， LONG JH. Advances in studies on Scutellariae Barbatae Herba[J]. Chin Tradit Herb Drug， 2010，41（8）：1406-1408. [3] TAO G， BALUNAS MJ. Current therapeutic role and medicinal potential of Scutellaria barbata in Traditional Chinese Medicine and Western research [J]. J Ethnopharmacol， 2016， 182:170-180. [4] WU T， WANG Q， JIANG C， et al. Neo-clerodane diterpenoids from Scutellaria barbata with activity against Epstein-Barr virus lytic replication [J]. J Nat Prod. 2015， 78(3):500-509. [5] YANG XK， XU MY， XU GS， et al. In vitro and in vivo antitumor activity of scutebarbatine A on human lung carcinoma A549 cell lines [J]. Molecules， 2014， 19(7):8740-8751. [6] LI YY， TANG XL， JIANG T， et al. Bioassay-guided isolation of neo-clerodane diterpenoids from Scutellaria barbata [J]. J Asian Nat Prod Res， 2013， 15(9):941-949. [7] 康安，乔广军，张正伟，等. HPLC法同时测定半枝莲中黄酮和生物碱类成分[J].南京中医药大学学报，2013，29（5）：479-481. [8] KANG A， QIAO GJ， ZHANG ZW， et al. Simultaneous Determination of Flavones and Scutebarbatines in Scutellariae barbatae by HPLC[J]. J Nanjing Univ Tradit Chin Med， 2013，29（5）：479-481.
计量
- 文章访问数: 1209
- HTML全文浏览量: 14
- PDF下载量: 1136
下载:
